E. Loftus

Genetics · 2001–2018

A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 12 researchers here, as inferred from the citation graph.

Subfields

• Genetics — 68 citations into it; #1,134 of 6,854 by trust here, #436 by citations

Whom E. Loftus trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. W. Sandborn

Who trusts E. Loftus overall

1. Judy H. Cho
2. Daniel C. Baumgart
3. W. Sandborn
4. Z. Y. Kho
5. Lan Lin
6. Ashwin N. Ananthakrishnan
7. R. Sartor
8. P. Pacher
9. G. Kaplan
10. L. Peyrin-Biroulet

Papers from E. Loftus's perspective

Ordered by how strongly the researchers E. Loftus trusts endorse each paper. Same corpus, a different order for every researcher.

1. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. (Arthritis & Rheumatism)
2. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (Gastroenterology)
3. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (Canadian journal of gastroenterology = Journal canadien de gastroenterologie)
4. Infliximab maintenance therapy for fistulizing Crohn's disease. (New England Journal of Medicine)
5. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. (Gastroenterology)
6. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. (Gastroenterology)
7. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (Gastroenterology)
8. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease (Nature Genetics)
9. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (Gastroenterology)
10. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease (Nature)

Their papers

• ACG Clinical Guideline: Management of Crohn’s Disease in Adults (2018) — 1,274 citations
• Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) — 1,455 citations
• The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) — 763 citations
• The Natural History of Adult Crohn's Disease in Population-Based Cohorts (2010) — 993 citations
• Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort (2010) — 747 citations
• Risk factors for opportunistic infections in patients with inflammatory bowel disease. (2008) — 1,040 citations
• Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 (2007) — 683 citations
• Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease (2005) — 596 citations
• Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (2005) — 3,349 citations
• The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (2004) — 964 citations
• Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. (2004) — 3,211 citations
• PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis (2004) — 748 citations
• The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (2002) — 1,102 citations
• The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (2001) — 1,177 citations